Seer Board Defends Strategy Against Activist Investors Ahead of Annual Meeting
Event summary
- Seer's Board issued a letter to shareholders ahead of its July 28, 2026 Annual Meeting, urging support for its seven director nominees against activist investors Bradley Radoff and Michael Torok.
- Activist investors have submitted director nominations and three unsolicited acquisition proposals, each priced below Seer's balance sheet value.
- Seer highlights 67% installed base growth, 69% consumable kit sample volume growth, and 19.3% operating expense reduction in 2025.
- The company has repurchased approximately 13.2M shares at an average price of $1.86 since 2024, reducing net diluted shares by ~15%.
The big picture
Seer's defense against activist investors highlights the tension between short-term financial gains and long-term strategic value creation in the proteomics market. The company's focus on deep, unbiased proteomics positions it to potentially mirror the success of genomics over the past 20 years, but it must navigate governance challenges to realize this vision. With significant scientific progress and financial discipline, Seer aims to build a durable market position ahead of its Annual Meeting.
What we're watching
- Governance Dynamics
- Whether Seer's Board can maintain control against activist pressure and sustain its long-term strategy.
- Financial Discipline
- The pace at which Seer can continue reducing operating expenses while accelerating product launches.
- Market Positioning
- How Seer's deep, unbiased proteomics technology will scale and compete in the rapidly growing proteomics market.
Related topics